This Is The First Study Using Escalating Doses Of PF-03758309, An Oral Compound, In Patients With Advanced Solid Tumors
Status:
Terminated
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
This is the first study using PF-03758309, an oral compound, in patients with advanced solid
tumors. In this study different doses of PF-03758309 will be administered to different groups
of patients. The study will assess the compound's safety, the blood levels of PF-03758309
during the treatment and the effect of the compound on the tumor cells.